Abstract: A pharmaceutical composition containing urokinase and a physiological absorption enhancer comprising higher fatty acids, a polyalkylene glycol and calcium is disclosed. Whereas urokinase which is decomposed and inactivated in the stomach and is poorly absorbed from the intestinal tract cannot be orally administered, it can be orally administered in the form of the present composition by applying an enteric coating, because urokinase in the composition is highly absorbable from the intestinal tract. It is desirable in the present composition in view of the stability and sustained absorbability that urokinase is contained in said composition in the form of a liposome preparation in which the urokinase is incorporated in voids of the liposome. The components are incorporated in the present composition at a ratio of 0.01-2 mg. of the higher fatty acid, 0.01-5 mg. of the polyalkylene glycol and 0.0001-0.1 mg. of the calcium per 100 units of urokinase.

Abstract: A plastic container containing an infusion solution which may not allow deterioration of the infusion solution over a long period of time, is prepared by providing a container which is made of a flexible plastic material having a heat resistance able to withstand heat of autoclaving sterilization and which holds an infusion solution containing components which may easily deteriorate upon contact with oxygen; the container is packaged with a first packaging material which consists of a plastic material having a gas permeability and a heat resistance able to withstand the heat of autoclaving sterilization. The container packaged with the first packaging material is sterilized by autoclaving in an atmosphere of saturated steam containing substantially no oxygen. The packaged and sterilized container is cooled while substantially maintaining a pressure of autoclaving sterilization by introducing an inert gas into the atmosphere.